6-[1,4-dimethyl-5-(4-methyl-benzoyl)-1H-pyrrol-2-ylmethyl]-2H-pyridazin-3-one | 179383-39-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-[1,4-dimethyl-5-(4-methyl-benzoyl)-1H-pyrrol-2-ylmethyl]-2H-pyridazin-3-one
• 英文别名: 3-[[1,4-dimethyl-5-(4-methylbenzoyl)pyrrol-2-yl]methyl]-1H-pyridazin-6-one
• CAS: 179383-39-2
• 化学式: C₁₉H₁₉N₃O₂
• 分子量: 321.379
• InChiKey: DODQTGBMVBMRHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  63.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION
  申请人：Chen Ying-Nan Pan

  公开号：US20090192211A1

  公开（公告）日：2009-07-30

  The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer or other malignancies in a mammal, particularly a human. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.

  本发明涉及一种组合物，包括(a)环氧合酶-2抑制剂（“COX-2抑制剂”）和(b)组蛋白去乙酰化酶抑制剂（“HDAI”），用于同时、并发、分离或顺序使用，特别是用于治疗哺乳动物，尤其是人类的癌前结肠病变或结肠癌或其他恶性肿瘤。本发明还涉及包含这种组合物的制药组合物，以及使用这种组合物治疗癌前结肠病变（例如息肉）和结肠癌以及其他恶性肿瘤的方法，尤其是在哺乳动物中，特别是人类。本发明还涉及包含这种组合物的商业包装或产品。
• Pyrrole derivatives
  申请人：F. Hoffmann-La Roche AG

  公开号：EP0714895A1

  公开（公告）日：1996-06-05

  Pyrrole derivatives are described. These compounds are useful as anti-inflammatory agents in the treatment of inflammation and pain. The preparation of these compounds, their pharmaceutically acceptable salts, and pharmaceutical compositions containing these compounds, is also described.

  介绍了吡咯衍生物。这些化合物可用作治疗炎症和疼痛的消炎剂。此外，还介绍了这些化合物、其药学上可接受的盐类以及含有这些化合物的药物组合物的制备方法。
• Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders
  申请人：Müller Norbert

  公开号：US20110130390A1

  公开（公告）日：2011-06-02

  The invention concerns the use of a COX-2 inhibitor for the treatment of psychiatric disorders such as schizophrenia, delusional disorders, affective disorders, autism or tic disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders, depressive episodes, recurring depressive episodes, manic episodes and bipolar affective disorders. Moreover, the invention is concerned with the use of a COX-2 inhibitor, in particular celecoxib, in combination with a neuroleptic drug, in particular risperidone, or an antidepressant, for the treatment of psychiatric disorders such as schizophrenia, delusional disorders, affective disorders, autism or tic disorders.
• US5622948A
  申请人：——

  公开号：US5622948A

  公开（公告）日：1997-04-22
• [EN] COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CALCIUM MODULATING AGENT FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS<br/>[FR] COMPOSITIONS RENFERMANT UN INHIBITEUR SELECTIF A L'EGARD DE LA CYCLOOXYGENASE 2 ET UN AGENT DE MODULATION DU CALCIUM POUR LE TRAITEMENT DE LA DOULEUR, DE L'INFLAMMATION OU DE TROUBLES DUS A L'INFLAMMATION
  申请人：PHARMACIA CORP

  公开号：WO2004093813A2

  公开（公告）日：2004-11-04

  The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a calcium modulating agent in combination with a cyclooxygenase-2 selective inhibitor.